Integrated brain restoration after ischemic stroke - medical management, risk factors, nutrients, and other interventions for Managing Inflammation and Enhancing Brain Plasticity

Alternative Medicine Review

Volumn 14, Issue 1, 2009, Pages 14-35

  Kidd, Parris M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; C REACTIVE PROTEIN; CEREBROLYSIN; CITICOLINE; CLOPIDOGREL; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; ERYTHROPOIETIN; FISH OIL; FOLIC ACID; GLYCEROPHOSPHORYLCHOLINE; GRANULOCYTE COLONY STIMULATING FACTOR; HOMOCYSTEINE; ICOSAPENTAENOIC ACID; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; MAGNESIUM SULFATE; NERVE GROWTH FACTOR RECEPTOR; PENTIFYLLINE; PENTOXIFYLLINE; PYRIDOXINE; SERUM ALBUMIN; TISSUE PLASMINOGEN ACTIVATOR; VASODILATOR AGENT;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ANTICOAGULANT THERAPY; ANXIETY; BLOOD CLOT LYSIS; BONE PAIN; BRAIN; BRAIN CELL; BRAIN CORTEX; BRAIN EDEMA; BRAIN FUNCTION; BRAIN INJURY; BRAIN PROTECTION; CARDIOVASCULAR SYSTEM EXAMINATION; CELL MIGRATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSTRAINT INDUCED THERAPY; DIET SUPPLEMENTATION; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DOWN REGULATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EXERCISE; HUMAN; HYPERBARIC OXYGEN; INDUCED HYPOTHERMIA; LEG EDEMA; LIVER INJURY; LOW DRUG DOSE; MENTAL PERFORMANCE; MONOTHERAPY; MOVEMENT THERAPY; NERVE CELL PLASTICITY; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRACTICE GUIDELINE; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK MANAGEMENT; SHRIMP; SIDE EFFECT; STEM CELL TRANSPLANTATION; THERAPY EFFECT; TISSUE REGENERATION; TREATMENT RESPONSE;

ANTICOAGULANTS; BRAIN; BRAIN ISCHEMIA; HOMOCYSTEINE; HUMANS; HYPERBARIC OXYGENATION; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; PLATELET AGGREGATION INHIBITORS; RECOVERY OF FUNCTION; RECURRENCE; RISK FACTORS; STEM CELL TRANSPLANTATION; STROKE; THROMBOLYTIC THERAPY; VASODILATOR AGENTS;

EID: 65149094080     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Perlmutter D, Colman C. The Better Brain Book, New York, NY: Riverhead Books (Penguin Group); 2004.
2. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:E85-E151.
3. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007,115:E478-E534.
4. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998;29:415-421.
5. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:577-617.
6. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology 2005;64:817-820.
7. Hurtado O, Pradillo JM, Alonso-Escolano D, et al. Neurorepair versus neuroprotection in stroke. Cerebrovasc Dis 2006;21:54-63.
8. No authors listed. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
9. Patel SC, Levine SR, Tilley BC, et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001;286:2830- 2838.
10. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002;59:862-867.
11. Choi JH, Bateman BT, Mangla S, et al. Endovascular recanalization therapy in acute ischemic stroke. Stroke 2006;37:419-424.
12. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432-1438.
13. Olsen TS, Larsen B, Herning M, et al. Blood flow and vascular reactivity in collaterally perfused brain tissue. Evidence of an ischemic penumbra in patients with acute stroke. Stroke 1983;14:332-341.
14. Grotta JC. Acute stroke therapy at the millennium; consummating the marriage between the laboratory and bedside. The Feinberg lecture. Stroke 1999;30:1722-1728.
15. Shin DH, Moon GJ, Bang OY. Albumin therapy in acute stroke patients. J Neurol 2007;254:870-878.
16. Suarez JL Shannon L, Zaidat OO, et al. Effect of human albumin administration on clinical outcome and hospital cost in patients with subarachnoid hemorrhage. J Neurosurg 2004;100:585-590.
17. Belayev L, Liu Y, Zhao W, et al. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001;32:553-560.
18. Meyer BC, Hemmen TM, Jackson CM, Lyden PD. Modified National Institutes of Health Stroke Scale for use in stroke clinical trials: prospective reliability and validity. Stroke 2002;33:1261-1266.
19. Wayner DD, Burton GW, Ingold KU, Locke S. Quantitative measurement of the total, peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. The important contribution made by plasma proteins. FEBS Lett 1985;187:33-37.
20. The Field Administration of Stroke Therapy - Magnesium Phase 3 Clinical Trial. FAST-MAG Scientific Background, www.fastmag.info/sci-bkg. htm [Accessed November 15, 2008]
21. Aslanyan S, Weir CJ, Muir KW, et al. Magnesium for treatment of acute lacunar stroke syndromes: further analysis of the IMAGES trial. Stroke 2007;38:1269- 1273.
22. Saver JL, Kidwell C, Eckstein M, et al. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy- Magnesium (FAST-MAG) pilot trial. Stroke 2004;35:E106-E108.
23. Georgiadis D, Schwarz S, Aschoff A, Schwab S. Hemicraniectomy and moderate hypothermia in patients with severe ischemic stroke. Stroke 2002;33:1584-1588.
24. Georgiadis D, Schwarz S, Kollmar R, Schwab S, Endovascular cooling for moderate hypothermia in patients with acute stroke: first results of a novel approach. Stroke 2001;32:2550-2553.
25. Krieger DW, De Georgia MA, Abou-Chebl A, et al. Cooling for Acute Ischemic Brain Damage (COOL AID): an open pilot study of induced hypothermia in acute ischemic stroke. Stroke 2001;32:1847-1854.
26. Meloni BP, Zhu H, Knuckey NW. Is magnesium neuroprotective following global and focal cerebral ischaemia? A review of published studies, Magnes Res 2006;19:123-137.
27. Ladurner G, Kalvach P, Moessler H, Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial, J Neural Transm 2005;112:415-428.
28. Neubauer RA, End E. Hyperbaric oxygenation as an adjunct therapy in strokes due to thrombosis. A review of 122 patients. Stroke 1980;11:297-300.
29. Carson S, McDonagh M, Russman B, Helfand M. Hyperbaric oxygen therapy for stroke: a systematic review of the evidence. Clin Rehabil 2005;19:819-833.
30. Rockswold SB, Rockswold GL, Defillo A. Hyperbaric oxygen in traumatic brain injury. Neurol Res 2007;29:162-172.
31. Rogatsky GG, Shifrin EG, Mayevsky A. Optimal dosing as a necessary condition for the efficacy of hyperbaric oxygen therapy in acute ischemic stroke: a critical review. Neurol Res 2003;25:95-98.
32. Nighoghossian N, Trouillas P, Adeleine P, Salord F. Hyperbaric oxygen in the treatment of acute ischemic stroke, A double-blind pilot study. Stroke 1995;26:1369-1372.
33. Neubauer R, Neubauer V, Gerstenbrand F. Late treatment of severe brain injury with hyperbaric oxygenation. J Am Phys Surg 2005;10:58-59.
34. International Hyperbaric Medical Association. Clinical Hyperbaric Oxygen Therapy Facilities Willing to Treat Brain Injured Service Members. www.hyperbaricmedicalassociation.org/Location [Accessed November 13, 2008]
35. Neubauer RA, Gottlieb SF, Kagan RL. Enhancing "idling" neurons. Lancet 1990:335:542.
36. Doidge N. The Brain That Changes Itself. New York, NY: Viking; 2007.
37. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:1647-1652.
38. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008;118:2243-2251.
39. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007;49:2129-2138.
40. Elkind MS. Inflammation, atherosclerosis, and stroke. Neurologist 2006;12:140-148.
41. Kuo HK, Yen CJ, Chang CH, et al. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005:4:371- 380.
42. Muir KW, Weir CJ, Alwan W, et al. C-reactive protein and outcome after ischemic stroke. Stroke 1999;30:981-985.
43. Winbeck K, Poppert H, Etgen X et al. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 2002;33:2459-2464.
44. Arenillas JF, Alvarez-Sabin J, Molina CA, et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 2003;34:2463-2468.
45. Rallidis LS, Vikelis M, Panagiotakos DB, et al. Usefulness of inflammatory and haemostatic markers to predict short-term risk for death in middle- aged ischaemic stroke patients. Acta Neurol Scand 2008;117:415-420.
46. Bansal S, Ridker PM. Comparison of characteristics of future myocardial infarctions in women with baseline high versus baseline low levels of high- sensitivity C-reactive protein. Am J Cardiol 2007;99:1500-1503.
47. Correale J, Villa A. The neuroprotective role of inflammation in nervous system injuries. J Neurol 2004;251:1304-1316.
48. Farooqui AA, Horrocks LA, Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem 2007;101:577-599.
49. Kidd PM. Omega-3 DHA and EPA for cognition, behavior and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Altern Med Rev 2007;12:207-227.
50. Hossain MS, Hashimoto M, Gamoh S, Masumura S. Antioxidative effects of docosahexaenoic acid in the cerebrum versus cerebellum and brainstem of aged hypercholesterolemic rats. J Neurochem 1999;72:1133-1138.
51. Hong S, Gronert K, Devchand PR, et al. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003;278:14677-14687.
52. Bunea R, El Farrah K, Deutsch L. Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Altern Med Rev 2004;9:420-428.
53. Sampalis F, Bunea R, Pelland MF, et al. Evaluation of the effects of Neptune Krill Oil on the management of premenstrual syndrome and dysmenorrhea. Altern Med Rev 2003;8:171-179.
54. Deutsch L. Evaluation of the effect of Neptune Krill Oil on chronic inflammation and arthritic symptoms. J Am Coll Nutr 2007;26:39-48.
55. Simi A, Tsakiri N, Wang P, Rothwell NJ. Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans 2007;35:1122-1126.
56. McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1 and neutrophil-dependent mechanisms.J Neurosci 2007;27:4403-4412.
57. Boutin H, LeFeuvre RA, Horai R, et al. Role of IL-lalpha and IL-lbeta in ischemic brain damage.J Neurosci 2001;21:5528-5534.
58. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol 2006;147:S232-S240.
59. Gueorguieva I, Clark SR, McMahon CJ, et al. Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid hemorrhage. Br J Clin Pharmacol 2008;65:317-325.
60. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999;131:352-355.
61. Bots ML, Launer LJ, Lindemans J, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999;159:38-44.
62. Cui R, Moriyama Y, Koike KA, et al. Serum total homocysteine concentrations and risk of mortality from stroke and coronary heart disease in Japanese: the JACC Study. Atherosclerosis 2008;198:412-418.
63. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 2007;6:830-838.
64. Hankey GJ. Is homocysteine a causal and treatable risk factor for stroke? Lancet Neurol 2007;6:751-752.
65. Wang J, Huff AM, Spence JD, Hegele RA. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration. Clin Genet 2004;65:483-486.
66. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128.
67. Boers GH, Smals AG, Trijbels FJ, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-715.
68. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149- 1155.
69. Van den Berg M, Boers GH, Franken DG, et al. Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995;25:176-181.
70. Mudd SH, Finkelstein JD, Refsum H, et al. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Throm Vase Biol 2000;20:1704-1706.
71. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.JAMA 1997;277:1775-1781.
72. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230- 236.
73. Refsum H, Nurk E, Smith AD, et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and association with disease.J Nutr 2006;136:1731S-1740S.
74. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-1577.
75. Poli D, Antonucci E, Cecchi E, et al. Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke 2005;36:2159-2163.
76. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575.
77. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a metaanalysis. Lancet 2007;369:1876-1882.
78. D'Orlando KJ, Sandage BW Jr. Citicoline (CDP- choline): mechanisms of action and effects in ischemic brain injury. Neurol Res 1995;17:281-284.
79. Rao AM, Hatcher JF, Dempsey RJ. CDP-choline: neuroprotection in transient forebrain ischemia of gerbils. J Neurosci Res 1999;58:697-705.
80. Secades JJ, Alvarez-Sabin J, Rubio F, et al. Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis 2006;21:380-385.
81. Clark WM, Warach SJ, Pettigrew LC, et al. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology 1997;49:671-678.
82. Clark WM, Williams BJ, Selzer KA, et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999;30:2592-2597.
83. Warach S, Pettigrew LC, Dashe JF, et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol 2000;48:713-722.
84. Clark WM, Wechsler LR, Sabounjian LA, et al. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001;57:1595-1602.
85. Dávalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 2002;33:2850-2857.
86. Bolland K, Whitehead J, Cobo E, Secades JJ. Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. Pharm Stat 2008 July 21 [Epub ahead of print]
87. Aguglia E, Ban TA, Panzarasa RM, et al. Choline alphoscerate in the treatment of mental pathology following acute cerebrovascular accident. Funct Neurol 1993;8:S5-S24.
88. Barbagallo Sangiorgi G, Barbagallo M, Giordano M, et al. alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann N Y Acad Sci 1994;717:253-269.
89. Consoli D, Giunta V, Grillo G, et al. alpha-GPC in the treatment of acute cerebrovascular accident patients. Arch Med Interna 1993;45:13-23. [Article in Italian]
90. Gambi D, Onofrj M. Multicenter clinical study of efficacy and tolerability of choline alfoscerate in patients with deficits in higher mental function arising after an acute ischemic cerebrovascular attack. Geriatria 1994;6:91-98.
91. Tomasina C, Manzino M, Novello P, et al. Clinical study of the therapeutic effectiveness and tolerability of choline alfoscerate in 15 subjects with compromised cognitive functions subsequent to acute focal cerebral ischemia. Riv Neuropsichiatr Sci Affin 1996;37:21-28.
92. Mathew NT, Rivera VM, Meyer JS, et al. Double- blind evaluation of glycerol therapy in acute cerebral infarction. Lancet 1972;2:1327-1329.
93. Parnetti L, Amenta F, Gallai V. Choline alfoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev 2001;122:2041-2055.
94. Auteri A, Bova F, Chiarion C, et al. Protecting the brain during heart surgery: treatment with choline alfoscerate. Le Basi Raz Ter 1993;23:123-128.
95. Onishchenko LS, Gaikova ON, Yanishevskii SN. Changes at the focus of experimental ischemic stroke treated with neuroprotective agents. Neurosci Behav Physiol 2008;38:49-54.
96. Wirthensohn G, Beck FX, Guder WG. Role and regulation of glycerophosphorylcholine in rat renal papilla. Pflugers Arch 1987;409:411-415.
97. Vega J A, Cavallotti C, del Valle ME, et al. Nerve growth factor receptor immunoreactivity in the cerebellar cortex of aged rats: effect of choline alfoscerate treatment. Mech Ageing Dev 1993;69:119- 127.
98. Merzenich MM, Kaas JH, Wall J, et al. Topographic reorganization of somatosensory cortical areas 3b and 1 in adult monkeys following restricted deafferentation. Neuroscience 1983;8:33-55.
99. Mahncke HW, Bronstone A, Merzenich MM. Brain plasticity and functional losses in the aged: scientific bases for a novel intervention. Prog Brain Res 2006;157:81-109.
100. Eriksson PS, Perfilieva E, Björk-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998;4:1313-1317.
101. Kempermann G. Adult Neurogenesis. New York, NY: Oxford University Press; 2006.
102. Schwab M. Nogo and axon regeneration. Curr Opin Neurobiol 2004;14:118-124.
103. Yiu G, He Z. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 2006;7:617-627.
104. Allard T, Clark S A, Jenkins WM, Merzenich MM. Reorganization of somatosensory area 3b representations in adult owl monkeys after digital syndactyly.J Neurophysiol 1991;66:1048-1058.
105. Xerri C, Merzenich MM, Peterson BE, Jenkins W. Plasticity of primary somatosensory cortex paralleling sensorimotor skill recovery from stroke in adult monkeys. J Neurophysiol 1998;79:2119-2148.
106. Jenkins WM, Merzenich MM, Ochs MT, et al. Functional reorganization of primary somatosensory cortex in adult owl monkeys after behaviorally controlled tactile stimulation.J Neurophysiol 1990;63:82-104.
107. Gerloff C, Bushara K, Sailer A, et al. Multimodal imaging of brain reorganization in motor areas of the contralesional hemisphere of well recovered patients after capsular stroke. Brain 2006;129:791-808.
108. Bhardwaj RD, Curtis MA, Spalding KL, et al. Neocortical neurogenesis in humans is restricted to development. Proc Natl Acad Sci USA 2006;103:12564-12568.
109. Hess DC, Borlongan CV. Stem cells and neurological diseases. Cell Prolif 2008;41:94-114.
110. Azizi SA, Stokes D, Augelli BJ, et al. Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats - similarities to astrocyte grafts. Proc Natl Acad Sci USA 1998;95:3908-3913.
111. Chen J, Li Y, Katakowski M, et al. Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Neurosci Res 2003;73:778-786.
112. Shen LH, Li Y, Chen J, et al. Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab 2007;27:6-13.
113. Liu H, Honmou O, Harada K, et al. Neuroprotection by P1GF gene-modifed human mesenchymal stem cells after cerebral ischaemia. Brain 2006,429:2734- 2745.
114. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005;57:874-882.
115. Steenblock D, Payne A. Umbilical Cord Stem Cell Therapy, Laguna Beach, CA: Basic Health Publications; 2006.
116. Locatelli F, Bersano A, Ballabio E, et al. Stem cell therapy in stroke. Cell Mol Life Sci 2008 Nov 8 [Epub ahead of print]
117. Minger SL, Ekonomou A, Carta EM, et al. Endogenous neurogenesis in the human brain following cerebral infarction. Regen Med 2007;2:69-74.
118. Arvidsson A, Collin T, Kirik D, et al. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 2002;8:963-970.
119. Skaper SD. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 2008;7:46-62.
120. Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001;2:24-32.
121. Tönges L, Schlachetzki JC, Weishaupt JH, Bahr M. Hematopoietic cytokines - on the verge of conquering neurology. Curr Mol Med 2007;7:157- 170.
122. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
123. Springborg JB, Møller C, Gideon P, et al. Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir (Wien) 2007;149:1089-1101.
124. Ehrenreich H, Timner W, Siren AL. A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia. Transfus Apher Sci 2004;31:39-44.
125. Liu XB, Wang JA, Yu SP, et al. Therapeutic strategy of erythropoietin in neurological disorders. CNS Neurol Disord Drug Targets 2008;7:227-234.
126. Schäbitz WR, Kollmar R, Schwaninger M, et al. Neuroprotective effect of granulocyte colony- stimulating factor after focal cerebral ischemia. Stroke 2003;34:745-751.
127. Borlongan CV, Hess DC. New hope for stroke patients: mobilization of endogenous stem cells. CMAJ 2006;174:954-955.
128. Shyu WC, Lin SZ, Lee CC, et al. Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial. CMAJ 2006; 174:927- 933.
129. Miller ER 3rd, Pastor-Barriuso R, Dalai D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
130. Milman U, Blum S, Shapira C, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Tbromb Vase Biol 2008;28:341-347.
131. Cramer SC. Repairing the human brain after stroke. II. Restorative therapies. Ann Neurol 2008;63:549- 560.
132. Wolf SL, Winstein CJ, Miller JP, et al. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. JAMA 2006;296:2095-2104.
133. Wolf SL, Winstein CJ, Miller JP, et al. Retention of upper limb function in stroke survivors who have received constraint-induced movement therapy: the EXCITE randomised trial. Lancet Neurol 2008;7:33- 40.
134. PositScience. Published and unpublished studies-all. www.positsci.com/ science [Accessed November 13, 2008]
135. Tanielian T, Jaycox L. Invisible Wounds of War: Psychological and Cognitive Injuries, Their Consequences, and Services to Assist Recovery, Santa Monica, CA: RAND Corporation; 2008.